Blood Cancer Journal· 2026Q1
REVEAL-MM: retrospective evaluation of variables in early assessment and landmark trends in multiple myeloma—a US claims-based case-control study
- 0citations
- Q1SCImago
- 2026year
Short summary
A machine learning model achieved an AUC of 0.826 at 6 months prior to diagnosis, identifying distinct healthcare utilization patterns that signal early Multiple Myeloma (MM) risk using US administrative claims data.
AI-generated from the title and abstract; the full text is not read.
Key points
- A machine learning model predicted Multiple Myeloma (MM) risk with an AUC of 0.826 at 6 months before diagnosis.
- The study analyzed US administrative claims data from 9,466 patients in a case-control design.
- Predictive performance of models increased as diagnosis approached.
- Healthcare utilization patterns like anemia-, musculoskeletal-, and M-protein–related testing were identified as early MM signals.
AI-generated from the title and abstract; the full text is not read.
Abstract
Abstract Multiple myeloma (MM) frequently presents with non-specific symptoms that overlap other common conditions, often leading to diagnostic delays and poorer clinical outcomes. Although diagnostic delays in MM are well recognized, the healthcare utilization patterns that precede MM diagnosis are not well defined. This retrospective, 1:1 matched case-control study used US administrative claims data from 9466 patients to identify early signals of MM and evaluate whether such data could be used to predict individuals at risk of MM prior to their formal diagnosis. All diagnostic, procedural, prescription, and physician-visit claims were evaluated at 12, 9, and 6 months within the two years before diagnosis. Interpretable predictive models (LASSO and Random Forest) identified distinct encounter patterns associated with MM as early as 12-months before diagnosis. Predictive performance across all models increased as diagnosis approached, with the machine learning model reaching a peak area under the curve (AUC) of 0.826 at 6 months. Claims consistent with typical MM manifestations, including anemia-, musculoskeletal-, and M-protein–related testing, were more common prior to MM diagnosis. These findings suggest that routinely collected claims data could support earlier identification and evaluation of individuals at risk of MM, enabling more timely diagnosis and improved outcomes.
The authors' abstract, as published at the source. Blood Cancer Journal, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Hematology
HematologyMedicine